YOUR BUSINESS AUTHORITY
Springfield, MO
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is preparing to submit an Alzheimer’s drug to the U.S. Food and Drug Administration for approval after assistance from Citizens Memorial Hospital in Bolivar.
The CMH Missouri Memory Center participated in a nationwide clinical trial with positive results in Alzheimer’s disease treatment, according to a news release. Eli Lilly's donanemab drug would be used for early-symptomatic Alzheimer’s patients.
“Alzheimer’s disease is the most common form of dementia, and it starts subtly but progresses relentlessly,” said Dr. Curtis Schreiber, medical director of the Missouri Memory Center and CMH Research Department, in the release. “While medications are currently available for treating the symptoms of Alzheimer’s, researchers continue to explore scientific approaches to actually slowing the progression of the symptoms.
"Options for slowing this unforgiving disease may be on the horizon.”
The Phase III study that CMH participated in found 47% of patients who used donanemab showed no decline based on a key measure of disease severity during the first year; had a 40% less decline in their ability to perform daily living activities at 18 months; and had a 39% lower risk of progressing to the next stage of the disease.
"We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer's disease in this trial," said Dr. Daniel Skovronsky, Lilly's chief scientific and medical officer, in a separate news release.
After discovering a niche for vintage typewriters, Laura Prather quickly grew a home-based typewriter sale and service business.
Physician sues CoxHealth, alleging business interference and defamation
Wendy’s franchisee ordered to pay $7M over harassment, PPP fraud accusations
Former PFH execs sentenced to prison time
Springfield CPA pleads guilty to embezzlement scheme
Updated: First Watch business partner sues another for breach of fiduciary duty, fraud